Replies to post #44110 on Innovation Pharmaceuticals Inc (IPIX)

[akamaii]

If ino got this deal on preclinical our b p and k has so much more potential. 10 million upfront on preclinical with 420 million potential deal. Inovio Reaches Licensing Pact With Roche Valued at up to $423 Million

By Tess Stynes

Inovio Pharmaceuticals Inc. (INO) said pharmaceutical giant Roche Holding AG (RHHBY, ROG.VX, RO.EB) will pay as much as $422.5 million in an exclusive licensing agreement for Invio's investigational gene-based vaccines for prostate cancer and hepatitis B.

Inovio's shares were up 33% at $2.96 in recent premarket trading.

The companies will collaborate on the two compounds--known as INO-5150 for prostate cancer and INO-1800 for hepatitis B--which are in preclinical development.

Under the agreement, Roche will pay $10 million upfront and as much as $412.5 million in milestone payments. Additional development milestone payments could also be made if Roche pursues using the compounds to treat other illnesses.

Inovio is entitled to receive up to double-digit tiered royalties on any product sales. Roche also obtained an option to license additional vaccine opportunities in connection with a collaborative cancer research program.

Roche's American depositary shares closed Monday at $63.39 and were inactive premarket.

Write to Tess Stynes at [e-mail]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

[dmattingly62]

Truth, you are probably right and I have no idea who they are. However, I had a large position in Ym bioscience for about 2 years and Sierra came out and said that Abbot Labs was looking to take them out and a few weeks later Ym was taken out by Gilead. I can't make this stuff up. You could probably find it on the web. They made another prediction on another holding I had, Keryx. I can't remember what it was, but Keryx was in the two's. A few months later is was up 5 fold. So I don't know. The only other time I saw a Sierra headline was a penny stock called Amarantus but that didn't do sh_t. Lol